RNA sequencing of sorafenib-sensitive Huh-7 cells versus sorafenib resistant Huh-7/SR1 and Huh-7/SR2 cells

Sorafenib is the global standard of care for patients with advanced hepatocellular carcinoma. It has marginal efficacy and patients invariably develop therapeutic resistance. The primary goal of this project was to comprehensively chratcerize the molecular profile of sorafenib resistant Huh-7/SR1 and Huh-7/SR2 cells compared to their parental counterpart Huh-7 cells, and discover potential new druggable targets which can overcome sorafenib resistance. Overall design: Sorafenib sensitive Huh-7 cells were treated with escalating doses of sorafenib to a maximum concentration of 10 microM for 3 months. Cell titre assay was used to confirm high EC50 of sorafenib in sorafenib-resistant Huh-7 cell lines. The cells were continuously maintained with 10 microM sorafenib. Total RNA was extracted using miRVana miRNA isolation kit. RNA integrity was tested using bioanalyzer. Three replicates of Huh-7 cells, Huh-7/SR1 cells and Huh-7/SR2 cells were send for RNA sequencing to Australian Genome Research Facility.